NAFTA 2.0 U.S. Poll Results

A recent poll shows that Americans oppose longer monopolies for big brand name pharmaceutical companies in NAFTA 2.0.

View Infographic
Generic Drugs are the Prescription for Savings

More than 9 out of 10 generic drug prescriptions are filled for $20 or less.

View Infographic
Patients Can See Their Savings

For the first time ever, the Association for Accessible Medicines is releasing savings data for 20 common patient conditions.

Learn More
Preserve Patient Access in Trade Agreements

Extending monopolies for brand-name drugs in trade agreements only increases patient drug prices. How? The new NAFTA deal decreases drug price competition.

Learn More
Skyrocketing Drug Prices are a Threat to Everyone

Use this infographic to learn how generics and biosimilars are a remedy to sky-high health care costs.

Read Blog

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Society

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Applauding Nomination of Dr. Scott Gottlieb to Lead the FDA

Oct 11, 2018 | Rachel Schwartz

AAM Statement on FDA Record Generic Approvals

New NAFTA - Proposed US-Mexico-Canada Agreement (USMCA)

Oct 9, 2018 | Jeff Francer

Op-Ed: The New NAFTA Could Thwart President's Promise to Lower Prescription Drug Costs

Direct Relief and AAM - Generic Prescriptions, AAM Member

Oct 4, 2018 | Rachel Schwartz

Prescription for Hope: AAM and Direct Relief

New NAFTA - Proposed US-Mexico-Canada Agreement (USMCA)

Oct 1, 2018 | Rachel Schwartz

AAM Opposes Barriers to Generic Drug and Biosimilar Access in Proposed US-Mexico-Canada Agreement (USMCA)

Sep 24, 2018 | Rachel Schwartz

Dana Mariani Joins AAM as Director, Policy

Sep 21, 2018 | Michael Brzica

$13.4 Billion a Year! Brand “Shenanigans” Are Costing Patients More Than Ever